BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22516806)

  • 21. The value of trefoil factor 3 expression in predicting the long‑term outcome and early recurrence of colorectal cancer.
    Morito K; Nakamura J; Kitajima Y; Kai K; Tanaka T; Kubo H; Miyake S; Noshiro H
    Int J Oncol; 2015 Feb; 46(2):563-8. PubMed ID: 25405728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Apr; 21(2):350-358. PubMed ID: 26370256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Oncol Rep; 2012 Sep; 28(3):855-61. PubMed ID: 22711167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.
    Yeo SG; Kim DY; Park JW; Oh JH; Kim SY; Chang HJ; Kim TH; Kim BC; Sohn DK; Kim MJ
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e193-9. PubMed ID: 21605941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study.
    Wang LW; Hsiao CF; Chen WT; Lee HH; Lin TC; Chen HC; Chen HH; Chien CR; Lin TY; Liu TW
    J Surg Oncol; 2014 May; 109(6):580-5. PubMed ID: 24374744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
    Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
    Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
    De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C
    Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
    Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the value of carcinoembryonic antigen reduction ratio as a prognosis factor in rectal cancer.
    Huang CS; Lin JK; Wang LW; Liang WY; Lin CC; Lan YT; Wang HS; Yang SH; Jiang JK; Chen WS; Lin TC; Chang SC
    Am J Surg; 2014 Jul; 208(1):99-105. PubMed ID: 24524862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caveolin-1 as a prognostic marker for local control after preoperative chemoradiation therapy in rectal cancer.
    Rödel F; Capalbo G; Rödel C; Weiss C
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):846-52. PubMed ID: 19131184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
    Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence.
    An HJ; Yu CS; Yun SC; Kang BW; Hong YS; Lee JL; Ryu MH; Chang HM; Park JH; Kim JH; Kang YK; Kim JC; Kim TW
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):73-80. PubMed ID: 22300562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of lymph node retrieval and lymph node ratio following preoperative chemoradiation of rectal cancer.
    La Torre M; Mazzuca F; Ferri M; Mari FS; Botticelli A; Pilozzi E; Lorenzon L; Osti MF; Marchetti P; Enrici RM; Ziparo V
    Colorectal Dis; 2013 Jul; 15(7):e382-8. PubMed ID: 23581854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy.
    Yoon G; Park JY; Kim HJ; Choi GS; Kim JG; Kang BW; Kang MK; Seo AN
    Anticancer Res; 2019 Jun; 39(6):2845-2853. PubMed ID: 31177122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
    Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study.
    Hongo K; Kazama S; Tsuno NH; Ishihara S; Sunami E; Kitayama J; Watanabe T
    World J Surg Oncol; 2015 Jan; 13():7. PubMed ID: 25622595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.